MARKET PULSE Shares of Reata Pharmaceuticals Inc. (RETA) soared about 175% in premarket trading on Wednesday, the day after the Food and Drug Administration approved Skyclarys, a treatment for Friedreich’s ataxia, a rare disease that affects an estimated 6,000 people in the U.S.
ほしにねがいを
MARKET PULSE Shares of Reata Pharmaceuticals Inc. (RETA) soared about 175% in premarket trading on Wednesday, the day after the Food and Drug Administration approved Skyclarys, a treatment for Friedreich’s ataxia, a rare disease that affects an estimated 6,000 people in the U.S.
ここの株買っているやつでFriedreich’s ataxiaがどんな病気か知る人はいないであろう、、、アメリカに6000人しかいない病気など知る由もない、、、